203 related articles for article (PubMed ID: 38476610)
21. Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment
Xu W; Lu J; Liu WR; Anwaier A; Wu Y; Tian X; Su JQ; Qu YY; Yang J; Zhang H; Ye D
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040418
[TBL] [Abstract][Full Text] [Related]
22. Development of a novel gene signature to predict prognosis and response to PD-1 blockade in clear cell renal cell carcinoma.
Yin X; Wang Z; Wang J; Xu Y; Kong W; Zhang J
Oncoimmunology; 2021; 10(1):1933332. PubMed ID: 34262797
[TBL] [Abstract][Full Text] [Related]
23. A comprehensive analysis of MYO6 as a promising biomarker for diagnosis, prognosis, and immunity in clear cell renal cell carcinoma.
Meng W; Chen B; Jiang Z; Cai B; Ma L; Guan Y
Transl Cancer Res; 2023 Aug; 12(8):2071-2098. PubMed ID: 37701098
[TBL] [Abstract][Full Text] [Related]
24. Endosialin-positive tumor-derived pericytes promote tumor progression through impeding the infiltration of CD8
Lu T; Zhang J; Lu S; Yang F; Gan L; Wu X; Song H; Liu S; Xu C; Han D; Yang B; Wen W; Qin W; Yang L
Cancer Immunol Immunother; 2023 Jun; 72(6):1739-1750. PubMed ID: 36646951
[TBL] [Abstract][Full Text] [Related]
25. Immune-related long non-coding RNAs can serve as prognostic biomarkers for clear cell renal cell carcinoma.
Li CS; Lu ZZ; Fang DL; Zhou WJ; Wei J
Transl Androl Urol; 2021 Jun; 10(6):2478-2492. PubMed ID: 34295734
[TBL] [Abstract][Full Text] [Related]
26. LINC00887 Fosters Development of Clear Cell Renal Cell Carcinoma via Inhibiting CD8+ T Cell Immune Infiltration.
Wu J; Lin R; Zhang L; Wei Y; Zhang R; Cai W; Hu W
Comput Math Methods Med; 2022; 2022():2582474. PubMed ID: 36060659
[TBL] [Abstract][Full Text] [Related]
27. Wiskott-Aldrich syndrome gene as a prognostic biomarker correlated with immune infiltrates in clear cell renal cell carcinoma.
Ding G; Wang T; Liu S; Zhou Z; Ma J; Wu J
Front Immunol; 2023; 14():1102824. PubMed ID: 37122750
[TBL] [Abstract][Full Text] [Related]
28. MiR-224 Executes a Tumor Accelerative Role during Hepatocellular Carcinoma Malignancy by Targeting Cytoplasmic Polyadenylation Element-Binding Protein 3.
Miao K; Liu SD; Huang WX; Dong H
Pharmacology; 2020; 105(7-8):477-487. PubMed ID: 32454494
[TBL] [Abstract][Full Text] [Related]
29. KL is a favorable prognostic factor related immune for clear cell renal cell carcinoma.
Pan KH; Yao L; Chen Z; Sun J; Jia Z; Zhang J; Ling Z
Eur J Med Res; 2023 Sep; 28(1):356. PubMed ID: 37726833
[TBL] [Abstract][Full Text] [Related]
30. Multi-omics profiles refine L-dopa decarboxylase (DDC) as a reliable biomarker for prognosis and immune microenvironment of clear cell renal cell carcinoma.
Chang K; Su J; Li C; Anwaier A; Liu W; Xu W; Qu Y; Zhang H; Ye D
Front Oncol; 2022; 12():1079446. PubMed ID: 36544704
[TBL] [Abstract][Full Text] [Related]
31. Identify AGAP2 as prognostic biomarker in clear cell renal cell carcinoma based on bioinformatics and IHC staining.
Xu Z; Wang Y; Xu J; Ang X; Ge N; Xu M; Pei C
Heliyon; 2023 Feb; 9(2):e13543. PubMed ID: 36846683
[TBL] [Abstract][Full Text] [Related]
32. Assessment of the prognostic value of
Chen J; Ye Z; Liu L; Xuan B
Transl Androl Urol; 2022 Apr; 11(4):509-518. PubMed ID: 35558273
[TBL] [Abstract][Full Text] [Related]
33. LZTS2: A novel and independent prognostic biomarker for clear cell renal cell carcinoma.
Peng Y; Greenland NY; Lang UE; Stohr BA
Pathol Res Pract; 2022 Apr; 232():153831. PubMed ID: 35287088
[TBL] [Abstract][Full Text] [Related]
34. Intratumoral CXCL13
Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
[TBL] [Abstract][Full Text] [Related]
35. PBRM1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to Nivolumab in patients with ccRCC: a tumor marker prognostic study.
Chang Q; Sun J; Zhao S; Li L; Zhang N; Yan L; Fan Y; Liu J
Aging (Albany NY); 2023 Nov; 15(23):13753-13775. PubMed ID: 38048211
[TBL] [Abstract][Full Text] [Related]
36. Tumor-associated macrophage-derived chemokine CCL5 facilitates the progression and immunosuppressive tumor microenvironment of clear cell renal cell carcinoma.
Xu W; Wu Y; Liu W; Anwaier A; Tian X; Su J; Huang H; Wei G; Qu Y; Zhang H; Ye D
Int J Biol Sci; 2022; 18(13):4884-4900. PubMed ID: 35982911
[No Abstract] [Full Text] [Related]
37. High Hepcidin expression predicts poor prognosis in patients with clear cell renal cell carcinoma.
Tang Y; Ge S; Zheng X; Zheng J
Diagn Pathol; 2022 Dec; 17(1):100. PubMed ID: 36585741
[TBL] [Abstract][Full Text] [Related]
38. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance and tumor-immune infiltration of mTOR in clear cell renal cell carcinoma.
Li N; Chen J; Liu Q; Qu H; Yang X; Gao P; Wang Y; Gao H; Wang H; Zhao Z
PeerJ; 2021; 9():e11901. PubMed ID: 34458019
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of sirtuin family members and experimental verification identify SIRT5 as diagnostic biomarkers in clear cell renal cell carcinoma.
Peng LS; Duan SL; Li RQ; Bai ZY; Ou CL; Wang JP
PeerJ; 2023; 11():e15154. PubMed ID: 37096064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
